Compugen Ltd. - Ordinary Shares (CGEN) News
Filter CGEN News Items
CGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CGEN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CGEN News From Around the Web
Below are the latest news stories about COMPUGEN LTD that investors may wish to consider to help them evaluate CGEN as an investment opportunity.
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead. Compugen is responsible for running the Phase 1 trial. |
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitableWe're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits... |
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the |
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?Compugen (NASDAQ:CGEN) has had a rough three months with its share price down 19%. But if you pay close attention, you... |
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...Compugen Ltd (CGEN) showcases strong financial stability and strategic advancements in ovarian cancer treatments amidst competitive challenges. |
Compugen (CGEN) Q3 Earnings and Revenues Lag EstimatesCompugen (CGEN) delivered earnings and revenue surprises of -83.33% and 3.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Compugen: Q3 Earnings SnapshotHOLON, Israel (AP) — Compugen Ltd. (CGEN) on Tuesday reported net income of $1.3 million in its third quarter. The Holon, Israel-based company said it had net income of 1 cent per share. The drug developer posted revenue of $17.1 million in the period. |
Compugen Reports Third Quarter 2024 ResultsCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. |
Compugen to Participate in Stifel 2024 Healthcare ConferenceCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2024 Healthcare Conference in New York City. The fireside chat will take place on Monday, November 18, 2024 at 8:35 am ET. |
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). |